CN117915911A - 使用三硫化物化合物的防止肝细胞生长因子中的酪氨酸残基的硝化的方法 - Google Patents
使用三硫化物化合物的防止肝细胞生长因子中的酪氨酸残基的硝化的方法 Download PDFInfo
- Publication number
- CN117915911A CN117915911A CN202280060120.3A CN202280060120A CN117915911A CN 117915911 A CN117915911 A CN 117915911A CN 202280060120 A CN202280060120 A CN 202280060120A CN 117915911 A CN117915911 A CN 117915911A
- Authority
- CN
- China
- Prior art keywords
- trisulfide
- compound
- pharmaceutically acceptable
- acceptable salt
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D341/00—Heterocyclic compounds containing rings having three or more sulfur atoms as the only ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021146753 | 2021-09-09 | ||
| JP2021-146753 | 2021-09-09 | ||
| PCT/JP2022/033764 WO2023038088A1 (ja) | 2021-09-09 | 2022-09-08 | トリスルフィド化合物を用いる、肝細胞増殖因子中のチロシン残基のニトロ化を防止する方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117915911A true CN117915911A (zh) | 2024-04-19 |
Family
ID=85506410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280060120.3A Pending CN117915911A (zh) | 2021-09-09 | 2022-09-08 | 使用三硫化物化合物的防止肝细胞生长因子中的酪氨酸残基的硝化的方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240374561A1 (https=) |
| EP (1) | EP4400103A4 (https=) |
| JP (1) | JP7659282B2 (https=) |
| CN (1) | CN117915911A (https=) |
| TW (1) | TW202321270A (https=) |
| WO (1) | WO2023038088A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025237108A1 (zh) * | 2024-05-11 | 2025-11-20 | 四川大学 | 一种多硫化物聚合物、其制备方法及应用 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4647072A1 (en) * | 2023-03-07 | 2025-11-12 | Kyowa Hakko Bio Co., Ltd. | Enhancer of physiological activity of hepatocyte growth factor |
| WO2025028521A1 (ja) | 2023-08-01 | 2025-02-06 | キリンホールディングス株式会社 | 肝機能障害の予防又は改善用組成物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5442173B2 (ja) * | 2000-09-14 | 2014-03-12 | 敏一 中村 | 筋萎縮性側索硬化症治療剤 |
| WO2018091689A1 (en) * | 2016-11-17 | 2018-05-24 | Cytoo | Skeletal muscle hypertrophy inducers |
| EP3560947B1 (en) | 2016-12-20 | 2022-08-24 | Kyowa Hakko Bio Co., Ltd. | Crystal of glutathione trisulfide dihydrate and method for producing same |
| JP2022074166A (ja) * | 2019-01-30 | 2022-05-18 | 協和発酵バイオ株式会社 | ポリスルフィド化合物を含有する組成物 |
| CN113354615B (zh) * | 2020-03-02 | 2023-11-03 | 亚宝药业集团股份有限公司 | 一种α-硫辛酸杂质A的光化学制备方法 |
| JP7842033B2 (ja) * | 2020-05-12 | 2026-04-07 | ザ ジェネラル ホスピタル コーポレイション | 神経保護におけるグルタチオントリスルフィド（ｇｓｓｓｇ） |
| US12552764B2 (en) * | 2020-08-27 | 2026-02-17 | Kyowa Pharma Chemical Co., Ltd. | Trisulfide compound and clathrate thereof |
| EP4342464A4 (en) * | 2021-07-08 | 2025-06-04 | Kyowa Pharma Chemical Co., Ltd. | PROPHYLACTIC OR THERAPEUTIC MEDICINE FOR PARKINSON'S DISEASE |
-
2022
- 2022-09-08 TW TW111134055A patent/TW202321270A/zh unknown
- 2022-09-08 US US18/689,734 patent/US20240374561A1/en active Pending
- 2022-09-08 EP EP22867409.9A patent/EP4400103A4/en active Pending
- 2022-09-08 CN CN202280060120.3A patent/CN117915911A/zh active Pending
- 2022-09-08 WO PCT/JP2022/033764 patent/WO2023038088A1/ja not_active Ceased
- 2022-09-08 JP JP2023546987A patent/JP7659282B2/ja active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025237108A1 (zh) * | 2024-05-11 | 2025-11-20 | 四川大学 | 一种多硫化物聚合物、其制备方法及应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2023038088A1 (https=) | 2023-03-16 |
| WO2023038088A1 (ja) | 2023-03-16 |
| EP4400103A4 (en) | 2025-08-20 |
| JP7659282B2 (ja) | 2025-04-09 |
| US20240374561A1 (en) | 2024-11-14 |
| EP4400103A1 (en) | 2024-07-17 |
| TW202321270A (zh) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN117915911A (zh) | 使用三硫化物化合物的防止肝细胞生长因子中的酪氨酸残基的硝化的方法 | |
| JP4344235B2 (ja) | タキソール増強剤化合物 | |
| JP4344234B2 (ja) | タキソール増強剤化合物 | |
| JP6871858B2 (ja) | 抗体薬物コンジュゲート | |
| JP5149620B2 (ja) | ２価リンカーおよびその結合体 | |
| JP4806508B2 (ja) | 前立腺がん、脱毛症又は他の高アンドロゲン症候群の治療又は診断のためのアンドロゲン受容体サプレッサー | |
| AU2012360094B9 (en) | FGF receptor (FGFR) agonist dimeric compounds, process for the preparation thereof and therapeutic use thereof | |
| US20030195258A1 (en) | Taxol enhancer compounds | |
| EP2018165B1 (fr) | COMPOSES DIMERES AGONISTES DES RECEPTEURS DES FGFs | |
| CN112138171A (zh) | 抗体偶联药物、其中间体、制备方法及应用 | |
| CN102216260A (zh) | 氨基酸衍生物 | |
| EP4604963A2 (en) | Covalent inhibitors of wild-type and mutant pi3k and method of uses thereof | |
| WO2023183936A2 (en) | Combination therapy of a pi3k inhibitor and kras inhibitor and methods of use thereof | |
| CN120752036A (zh) | 肝细胞生长因子的生理活性增强剂 | |
| EP3237015B1 (fr) | Derives hydroxybisphosphoniques hydrosolubles de la doxorubicine | |
| JP2018535231A (ja) | チアジアゾール誘導体類のｄｐｐ−ｉｖ阻害剤の結晶及びその使用 | |
| HK1060117B (en) | Taxol enhancer compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |